Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease

M R B KEIGHLEY*, DENISE YOUNGS, MARGARET JOHNSON,
R N ALLAN, and D W BURDON

From The General Hospital, Birmingham

SUMMARY The incidence of *Clostridium difficile* cytotoxin has been studied in 69 consecutive patients with inflammatory bowel disease complicated by severe diarrhoea or ileostomy flux during 74 admissions to hospital. The cytotoxin was identified in only four patients, all of whom had received antimicrobials. *Clostridium difficile*, but not cytotoxin, was identified in 10 of 43 admissions. This followed antimicrobial prophylaxis to cover a recent operation in two patients, and five were on long-term sulphasalazine. Only three patients with *Clostridium difficile* had not received an antimicrobial within one month of the study. Isolation of *Clostridium difficile* alone is of doubtful pathological significance, as it spontaneously disappeared without treatment in all patients.

It has been suggested that *Clostridium difficile* toxin may be responsible for relapse in patients with inflammatory bowel disease.^{1,2} *Clostridium difficile* toxin has also been implicated in the pathogenesis of antibiotic associated colitis.^{3,4} The organism is not generally found in the faeces of healthy adults,⁵ but is present in 40%⁶ of normal neonates and the toxin is present in 14% of infants five months after birth.⁷ *Clostridium difficile* without toxin may be recovered from patients exposed to a variety of antimicrobials without any evidence of colitis and occasionally without diarrhoea.⁸ Many of the patients in whom *Clostridium difficile* has been identified during a relapse of inflammatory bowel disease^{1,2} were receiving maintenance sulphasalazine or systemic antibiotics. The purpose of this study has been to document the incidence of *Clostridium difficile* toxin in patients with acute diarrhoea or ileostomy flux complicating inflammatory bowel disease and to observe the natural history of *Clostridium difficile* in inflammatory bowel disease.

Methods

PATIENTS

All patients admitted to a single unit with symptomatic relapse of inflammatory bowel disease

between November 1978 and August 1980 were studied. Relapse referred either to patients with severe systemic disease and acute diarrhoea leading to dehydration (irrespective of the site of disease or previous operation), or to patients with an ileostomy output greater than 1 litre per day. Sixty-nine patients were investigated during 74 hospital admissions (Table 1). The reasons for admission included acute proctocolitis in 24, acute diarrhoea complicating small bowel Crohn's disease in 19, ileostomy flux in 10, and early postoperative diarrhoea or flux in 21. The underlying diagnosis included ulcerative colitis in 21. Crohn's disease was present in 48 patients three of whom also had an

Table 1 Comparison between phase 1 and phase 2 (patients)

	Phase 1 (39) Toxin+Cl difficile	Phase 2 (30) Toxin
Age (yr)		
20-40	13	15
40-60	14	9
More than 60	12	6
Medication		
Steroids	14	9
Sulphasalazine	17	11
Diagnosis		
Ulcerative colitis	12	9
Crohn's disease	27	21
Other	1	—

* Address for correspondence: M R B Keighley, The General Hospital, Steelhouse Lane, Birmingham B4 6NH.

Received for publication 14 September 1981

associated carcinoma of the small (one) or large intestine (two) and four who had other disorders: diverticular disease (two), coeliac disease (one), and peptic ulcer (one). Maintenance treatment in these 68 patients included systemic corticosteroids in 23 patients and sulphasalazine in 28. The mean age of the patients was 42.3 years (range: 21–91 years). One other patient had acute diarrhoea and appearances on sigmoidoscopy which suggested acute onset of inflammatory bowel disease, the subsequent course of this patient leaves us in no doubt, however, that she had pseudomembranous colitis.

TECHNIQUES

Stool specimens were collected during the acute illness for identification of *Clostridium difficile* cytotoxin. The toxin was demonstrated from serial dilutions of a faecal suspension placed on a mono layer of HeLa cells.⁹ If the toxin was present, there was rounding and clumping of cells which became separated from one another. This appearance was neutralised by *Clostridium sordellii* antitoxin. *Clostridium difficile* was isolated on lysed blood agar containing 70 mg/l kanamycin and on 7% blood agar containing 500 mg/l cycloserine and 16 mg/l cefoxitin. Broth cultures of *Clostridium difficile* were tested for production of neutralised toxin on HeLa cells. Because of the work load in the laboratory, routine culture of stool specimens for *Clostridium difficile* was discontinued in January 1980. During the last eight months faecal samples were screened for presence of cytotoxin and examination for *Clostridium difficile* was undertaken only if toxin was identified. For clarity the two parts of the study will be referred to as phase 1 (toxin and organism) and phase 2 (toxin alone). The age, regular medical therapy, or diagnosis of patients in phase 1 or phase 2 is shown in Table 2.

Results (Table 2)

One patient (no. 1) was admitted with a one-month history of diarrhoea; she had previously received co-trimoxazole and the appearances on sigmoidoscopy suggested acute proctocolitis. A biopsy confirmed pseudomembranous colitis (Table 3) and *Clostridium difficile* and cytotoxin were found. Treatment with vancomycin eradicated the toxin and organism. The patient has had no further bowel symptoms during a follow-up of 18 months and we believe she was suffering from antibiotic associated colitis. This patient was excluded from subsequent analysis. Three patients (nos 2–4) acquired *Clostridium difficile* cytotoxin after an operation for Crohn's disease and in each case they had received antimicrobial prophylaxis. Two of these patients

Table 2 Details of admission samples with results

Reason for admission	Phase 1 n: Toxin + Cl. difficile	Phase 2 n: Toxin (only Cl. difficile if toxin + ve)
Acute proctocolitis (24)	14:1+7	10:0
Acute diarrhoea (19)	8:0+2	11:0
Ileostomy flux (10)	6:0+0	4:0
Postoperative (21)	15:3+5	6:0
Total	43:4+14	31:0
No antibiotics except sulphasalazine (54)	31:0+8*	23:0
Antibiotics within one month of sample (20)	12:4+6	8:0

* Five on sulphasalazine.

were treated immediately with vancomycin with elimination of the toxin and a rapid clinical response. The third patient was discharged from hospital before the result of the cytotoxin test was known: the patient continued to have diarrhoea, repeat faecal samples revealed persistent excretion of *Clostridium difficile*, and subsequent treatment with vancomycin resulted in rapid clinical improvement and disappearance of the organism.

In 10 other patients, *Clostridium difficile* alone was recovered from the stool. Broth cultures of these clostridia all produced cytotoxin. Two patients (nos 5, 6) had been treated previously by total colectomy and ileorectal anastomosis and had received prophylactic antimicrobials. The eight remaining patients (nos 7–14) had been admitted with acute disease: four had acute ulcerative colitis, two had acute Crohn's colitis, and two had small intestinal Crohn's disease. Five of these patients, however, were receiving sulphasalazine for colitis, thus leaving only three who had not been recently exposed to an antibiotic. None of the patients with *Clostridium difficile* alone received specific therapy. All of the patients were re-investigated four to six weeks later, but in none was *Clostridium difficile* subsequently found in the stool. One of the patients, however, later developed a relapse of ulcerative colitis requiring colectomy. Although faecal cultures were negative for *Clostridium difficile*, the organism was identified from the submucosa of the resected colon.

Of the 54 patients with acute inflammatory bowel disease who had not received an antibiotic, other than sulphasalazine, within one month of the study, none had evidence of *Clostridium difficile* toxin. Thirty-one of these patients were studied during phase 1, and, of these, only eight (26%) had *Clostridium difficile* in their faeces.

Table 3 Details of patients with *Clostridium difficile* in stool

Number	Length of history of bowel disease (yr)	Age (yr)	Antibacterial agents prescribed within one month of samples	Presence of toxin	Final diagnosis	Recent operation	Site of inflammatory disease	Treatment	Identification of <i>C. difficile</i> from stool 4-6 w after treatment
1	1 month	52	Co-trimoxazole	Yes	AAC	No	LB	Vancomycin	None
2	15	53	Metronidazole Gentamicin	Yes	Crohn's	Total colectomy and ileorectal anastomosis	LB	Vancomycin	None
3	7	52	Ampicillin Metronidazole Gentamicin	Yes	Crohn's	Small bowel resection	SB	Vancomycin	None
4	10	49	Cefazolin Metronidazole	Yes	Crohn's	Post-anal repair	LB	Vancomycin (delayed)	None
5	7	36	Gentamicin Cefoxitin	No	Crohn's	Total colectomy and ileorectal anastomosis	LB	None	None
6	10	40	Metronidazole Cefazolin	No	Crohn's	Total colectomy and ileorectal anastomosis	LB	None	None
7	15	25	—	No	Crohn's	No	SB	None	None
8	3	36	—	No	Crohn's	No	LB	None	None
9	5	62	Sulphasalazine	No	U C	No	LB	None	None*
10	1	36	—	No	Crohn's	No	SB	None	None
11	4	67	Sulphasalazine	No	Crohn's	No	LB	None	None
12	11	76	Sulphasalazine	No	U C	No	LB	None	None
13	29	90	Sulphasalazine	No	U C	No	LB	None	None
14	7	52	Sulphasalazine	No	U C	No	LB	None	None

* *C. Difficile* in colon at operation

Discussion

This survey has shown that *Clostridium difficile* cytotoxin was identified in only four of the 74 episodes of severe diarrhoea complicating inflammatory bowel disease. This is in marked contrast with our experience in 88 patients with antibiotic-associated colitis or diarrhoea, where cytotoxin was identified in 61 (69%) and where *Clostridium difficile* alone was recovered in all of the remaining 27 cases (31%).¹⁰ One patient in this study was subsequently shown to have had antibiotic-associated colitis. The other three patients had undergone recent surgical treatment with antimicrobial prophylaxis. These patients did not differ clinically from many of the patients observed in this hospital who have had postoperative antibiotic-associated colitis.⁹ None of the patients had a rectal biopsy during the episode of diarrhoea, principally because of their underlying disease. Nevertheless, the manifestations of their disease and the rapid response to vancomycin¹¹ suggests that these patients had had a mild episode of antibiotic-associated colitis rather than intestinal colonisation by *Clostridium difficile* as a complication of their inflammatory disease. There were two other patients in whom the organism was recovered alone without cytotoxin after exposure to prophylactic antimicrobials given during colectomy and ileorectal anastomosis. The role of *Clostridium difficile* in causing the diarrhoea of these patients is uncertain. In our experience there are a small number of patients who have sigmoidoscopic or histological evidence of pseudomembranous colitis¹² in whom the organism is found in the absence of cytotoxin¹³ and we believe that these two patients may have been in this category. Furthermore, in untreated patients the presence of toxin may be transient and often disappears despite persistent excretion of *Clostridium difficile*. It is possible that the absence of toxin might be due to insufficient numbers of clostridia to produce a measurable level of cytotoxin or to production of only small amounts of toxin by the clostridia. *Clostridium difficile* but not cytotoxin was found in single stool specimens from the remaining eight patients. This probably represents colonisation by the organism but our data do not establish whether this coincided with the onset of relapse, particularly as repeated stool specimens were not cultured. These patients had not had an operation or been exposed to antimicrobials other than sulphasalazine, which was being used as maintenance therapy for ulcerative colitis or Crohn's disease. It is interesting that *Clostridium difficile* disappeared without treatment even though sulphasalazine treatment was continued. We believe

that colonisation of the colon by *Clostridium difficile* may occur more readily when the normal intestinal flora is disturbed. In hamsters colonisation by *Clostridium difficile* is associated with a reduction in the counts of anaerobic streptococci and corynebacteria.¹⁴ A fall in the counts of *Bacteroides* sp has also been observed when oral kanamycin or neomycin and metronidazole is used for bowel preparation,¹⁵ a regime which has been associated with antibiotic-associated colitis.¹⁶ The intestinal microflora is also abnormal with low anaerobic counts in patients with inflammatory bowel disease.¹⁷ We believe that such conditions favour the identification of *Clostridium difficile* and that their presence should not necessarily be regarded as pathological. Indeed, in all such patients seen in this survey the organisms spontaneously disappeared within six weeks without treatment. Sulphasalazine may be associated with an alteration of the normal faecal microflora¹⁸ which may also predispose these patients to colonisation by *Clostridium difficile*. We would conclude therefore that *Clostridium difficile* toxin is rare in patients with inflammatory bowel disease unless the patient has been exposed to antibiotics and the isolation of this organism is therefore of doubtful pathological significance.

References

- 1 LaMont, JT, Trnka YM. Therapeutic implications of *Clostridium difficile* toxin during relapse of chronic inflammatory bowel disease. *Lancet* 1980; **1**: 381-3.
- 2 Bolton RP, Sherriff RJ, Read AE. *Clostridium difficile* associated diarrhoea: a role in inflammatory bowel disease. *Lancet* 1980; **1**: 383-4.
- 3 Larson HE, Price AB, Honour P, Borriello SP. *Clostridium difficile* and the aetiology of pseudomembranous colitis. *Lancet* 1978; **1**: 1063-6.
- 4 Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic associated pseudomembranous colitis, due to toxin producing clostridia. *N Engl J Med* 1978; **298**: 531-4.
- 5 Larson HE. Pseudomembranous colitis is an infection. *J Infection*. 1979; **1**: 221-6.
- 6 George WL, Sutter VL, Finegold SM. Antimicrobial agent induced diarrhoea - a bacterial disease. *J Infect Dis* 1977; **136**: 822-8.
- 7 Rietra PJGM, Slaterus KW, Zanen HC, Menwissen SGM. Clostridial toxin in faeces of healthy infants. *Lancet* 1978; **2**: 319.
- 8 Lishman AH, Al Jumaili IJ, Record CO. Spectrum of antibiotic-associated diarrhoea. *Gut* 1981; **22**: 34-7.
- 9 Keighley MRB, Burdon DW, Alexander-Williams J, Shinagawa N, Arabi Y, Thompson H, Youngs D, Bentley S, George RH. Diarrhoea and pseudomembranous colitis after gastrointestinal operations.

- Lancet* 1978; **2**: 1165–7.
- 10 Burdon DW, Keighley MRB, Allan RN, George RH. Clostridial toxin in inflammatory bowel disease. *Lancet* 1980; **1**: 1421–2.
 - 11 Keighley MRB, Burdon DW, Arabi Y, Alexander-Williams J, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GAG. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. *Br Med J* 1978; **2**: 1667–9.
 - 12 Price AB, Davies DR. Pseudomembranous colitis. *J Clin Path* 1977; **30**: 1–12.
 - 13 Mogg GAG, Keighley MRB, Burdon DW, Alexander-Williams J, Youngs D, Johnson M, Bentley S, George RH. Antibiotic associated colitis – a review of 66 cases. *Br J Surg* 1979; **66**: 738–42.
 - 14 Lusk RH, Tekety R, Silva J, Browne RA, Ringler DH, Abrams GD. Clindamycin induced enterocolitis in hamsters. *J Infect Dis* 1978; **137**: 464–75.
 - 15 Arabi Y, Dimock F, Burdon DW, Alexander-Williams J, Keighley MRB. Influence of bowel preparation and antimicrobials on colonic microflora. *Br J Surg* 1978; **65**: 555–9.
 - 16 Keighley MRB, Arabi Y, Alexander-Williams J, Youngs D, Burdon DW. Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery. *Lancet* 1979; **1**: 894–7.
 - 17 Krook A, Danielsson D, Kyellander J, Janerot G. Changes in the faecal flora of patients with Crohn's disease during treatment with metronidazole. *Scand J Gastroenterol* 1979; **14**: 705–10.
 - 18 Krook A. *Microbiological and clinical studies on Crohn's disease*. Sweden: Thesis University of Uppsala, 1980.